As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.
8 Analysts have issued a Kintara Therapeutics Inc forecast:
8 Analysts have issued a Kintara Therapeutics Inc forecast:
Mar '25 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -27 -27 |
187%
187%
|
EBIT (Operating Income) EBIT | -27 -27 |
187%
187%
|
Net Profit | -32 -32 |
232%
232%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Kintara Therapeutics, Inc. is a clinical and biopharmaceutical company, which focuses on the development and commercialization of new cancer therapies. Its pipeline includes the VAL-083 and REM-001. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headquartered in San Diego, CA.
Head office | United States |
CEO | James Bianco |
Founded | 2009 |
Website | tuhurabio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.